RETA-PEN 10mg

FOR RESEARCH PURPOSE ONLY

RETA-PEN 10mg can provide 4 doses of 2.5mg.

Retatrutide (also known as LY-3437943) is an experimental medication developed by Eli Lilly that is being studied as a next-generation treatment for obesity, overweight, and related metabolic conditions such as type 2 diabetes. It represents a new class of therapies called “triple agonists,” meaning it simultaneously activates three key hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This combined activity helps regulate appetite, improve insulin sensitivity, slow gastric emptying to promote fullness, and enhance fat burning.

Key Points:
→ Retatrutide is given as a once-weekly subcutaneous injection.
→ Stepwise escalation is critical to reduce gastrointestinal intolerance.
→ Most participants in trials reached 8–12 mg weekly, which delivered the strongest results
→ Dosing protocols may be refined in Phase 3 and post-approval, but gradual titration will remain the standard.

Common Side Effects :

Across Phase 2 trials, participants experienced dose-dependent GI symptoms that are characteristic of GLP-1 receptor agonists:

• Nausea — most frequent, especially during dose escalation
• Vomiting — typically mild to moderate, subsiding with continued use
• Diarrhea and constipation — fluctuating depending on individual tolerance
• Abdominal discomfort — transient and often improved over time